ZITADEL
10.6.2022 11:50:09 CEST | Business Wire | Press release
ZITADEL, innovator of a transformative identity management platform, announces $2.5M in seed funding led by Nexus Venture Partners. The funding will help ZITADEL provide developers with a much-needed open-source alternative for their identity management needs and evolve its solution, scale sales growth, and nurture the open-source community. The current market landscape consists of established but closed-source players, including Auth0, Okta, Firebase, AWS Cognito, and others.
ZITADEL’s founding vision was based on the creation of a streamlined, cloud-native identity management platform to speed time-to-market for software projects. Focused on the simplicity of integration, ready-to-use self-service features, a customizable and secure login with first-class support for passwordless authentication, and an API-first strategy, ZITADEL’s unique turnkey platform offers developers unprecedented flexibility.
Developers often spend countless hours creating, configuring, and operating complex authentication and authorization systems. ZITADEL, which is built mainly in the Go programming language, solves these problems with easy-to-use integrations in multiple languages and frameworks. This flexibility enables developers to utilize prebuilt features provided by ZITADEL to dramatically improve their productivity. In addition, ZITADEL’s capabilities address existing open-source projects which were not built for a cloud-native and serverless environment.
The ZITADEL team is working towards further enriching the solution’s enterprise-readiness. New capabilities include multi-tenancy, unlimited audit trails, improved ability to self-host, and support for serverless deployments, plus the potential to extend ZITADEL’s breadth with custom code created in WebAssembly. Combined with its cloud-native architecture, ZITADEL’s self-hosting capabilities allow privacy-focused customers to own and control their data by running a dedicated version. ZITADEL’s flexible model, with its span of smart efficiency enhancements, is already the go-to solution for numerous marquee enterprise customers.
The generous free tier of ZITADEL’s cloud-hosted offering allows anybody to create a ZITADEL instance in under five minutes—without a credit card. In its ongoing commitment to deliver GDPR support to its customers, ZITADEL Cloud also provides the capability to define the country or geopolitical region in which to store their data.
“Amidst today's complex software projects, ZITADEL provides a turnkey solution that allows developers to get started easily with a secure login, user management, multi-factor authentication, social logins, authorization management, and great APIs. With ZITADEL, we provide an important component to improve the overall security of a project while reducing your time-to-market,” said ZITADEL Co-Founder and CEO, Florian Forster.
“We’re delighted to break new ground partnering with Florian and the ZITADEL team, our first-ever investment in a Swiss company. We believe the future of digital identities is passwordless. ZITADEL takes a developer-first, open-source approach to solving identity management. Its simple and easy-to-integrate building blocks help developers build secure authentication into their applications without requiring deep in-house expertise and resource commitment.” said Abhishek Sharma, Managing Director at Nexus Venture Partners. “ZITADEL is the latest addition to the Nexus family of over a dozen marquee commercial open-source companies,” added Sharma.
About ZITADEL
ZITADEL is the modern open* alternative for Auth0, Firebase Auth, and AWS Cognito, as well as Keycloak, built for the container and serverless era. It provides customers a wide range of out-of-the-box features, including secure login, self-service, OpenID Connect, OAuth2.x, SAML2, branding, Passwordless with FIDO2, OTP, U2F, and an unlimited audit trail to improve the life of developers and developers. With its legal incorporation in Switzerland, ZITADEL is in the unique position of providing its cloud services even to customers with the strictest GDPR requirements. For more information visit https://zitadel.com , follow @zitadel on Twitter, or star the repository https://github.com/zitadel/zitadel on GitHub
About Nexus Venture Partners
Nexus Venture Partners is an early-stage venture capital firm partnering with extraordinary entrepreneurs to help build product-first software companies. With $2 billion under management, Nexus operates as one team across the U.S. and India. The Nexus portfolio includes Apollo.io, Aryaka, Clover Health, Delhivery, Druva, FingerprintJS, Hasura, H2O.ai, Infra Market, Kaltura, MinIO, Observe.ai, Postman, Pubmatic, Quizizz, Rancher, Rapido, Sibros, TileDB, Turtlemint, Unacademy, WhitehatJr, and Zepto. For more information, visit www.nexusvp.com or follow @nexusvp on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220609005526/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom